New hope for tough bone cancer: experimental drug takes on chemo in Late-Stage trial
NCT ID NCT06935409
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called HS-20093 against a standard chemotherapy combination (gemcitabine plus docetaxel) in people with osteosarcoma (a type of bone cancer) that has not responded to at least two prior treatments. About 117 participants aged 12 and older will be randomly assigned to receive either the new drug or the standard chemo. The main goal is to see if HS-20093 can delay cancer growth or improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Jishuitan Hospital affiliated to Capital Medical University
Beijing, China
-
Peking University People's Hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a targeted pill stall advanced sarcomas?
- Can two drugs together fight Hard-to-Treat bone and Soft-Tissue cancers?
- Experimental vaccine fights sarcoma with Patient's own immune cells
- New drug hope for rare sarcomas after chemo fails
- Dietary change explored as cancer support strategy